Interestingly, CMML patients exhibit higher background concentrations of the above-mentioned pro-inflammatory cytokines, and these same pro-inflammatory mediators (IL-1β, IL-6, TNFα) have been reported to promote AML aggressiveness [15]. This evidence concerns the gene IL1B and chronic myelomonocytic leukemia.